ArticleCurrent oncology (Toronto, Ont.)2018
Evidence-based best practices for
Article in Current oncology (Toronto, Ont.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Clinical Practice Guideline for Blood-based Circulating Tumor DNA Assays.Annals of laboratory medicine · 2024Guideline
- Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing.Advances in therapy · 2019Guideline
- Plasma-Based Genomic Features Influencing Outcomes of T790M-Positive Non-Small Cell Lung Cancer Receiving Osimertinib.Cancer medicine · 2025Article
- Molecular testing, treatment patterns, and outcomes in EGFR-mutated non-small cell lung cancer: the PISCES study.Future oncology (London, England) · 2025Article
- Design, synthesis, docking, ADMET and anticancer evaluations ofRSC advances · 2023Article
- Leptomeningeal Metastatic L858ROncoTargets and therapy · 2022Article
- EGFR T790M Mutation Detection in Patients With Non-Small Cell Lung Cancer After First Line EGFR TKI Therapy: Summary of Results in a Three-Year Period and a Comparison of Commercially Available Detection Kits.Pathology oncology research : POR · 2022Article
- Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors.BMJ open respiratory research · 2022Article
- Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients.Current oncology (Toronto, Ont.) · 2021Article
- A Pan-Canadian Validation Study for the Detection ofJTO clinical and research reports · 2021Article
- Clinical implementation of circulating tumour DNA testing forJournal of clinical pathology · 2021Article
- Consensus recommendations for optimizing biomarker testing to identify and treat advancedCurrent oncology (Toronto, Ont.) · 2020Article
- Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib.Translational lung cancer research · 2020Article
- EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes.Translational lung cancer research · 2020Article
- Canadian consensus: a new systemic treatment algorithm for advancedCurrent oncology (Toronto, Ont.) · 2020Article
- Biopsy on progression in patients withCurrent oncology (Toronto, Ont.) · 2020Article
- Cell-Free Circulating Tumour DNA Blood Testing to DetectOntario health technology assessment series · 2020Article
- Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).Lung cancer (Amsterdam, Netherlands) · 2019Review
- A Canadian guideline on the use of next-generation sequencing in oncology.Current oncology (Toronto, Ont.) · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors (tkis) are recommended as first-line systemic therapy for patients with non-small-cell lung cancer (nsclc) having mutations in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.